Overview

A Two-arm, Single Center Phase 1b Trial of Bavituximab Plus Ipilimumab in Advanced Melanoma Patients

Status:
Terminated
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
This is a Open label, two-arm, randomized, two agent, single center trial.
Phase:
Phase 1
Details
Lead Sponsor:
University of Texas Southwestern Medical Center
Treatments:
Antibodies, Monoclonal
Bavituximab
Ipilimumab